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In recent years, autoantibodies targeting subcellular structures described as the rods
and rings pattern in HEp-2 ANA have been presented as a unique case of autoanti-
body generation. These rod and ring structures (RR) are at least partially composed of
inosine monophosphate dehydrogenase type 2 (IMPDH2), and their formation can be
induced in vitro by several small-molecule inhibitors, including some IMPDH2 inhibitors.
Autoantibodies targeting these relatively unknown structures have been almost exclusively
observed in hepatitis C virus (HCV) patients who have undergone treatment with pegylated
interferon-α/ribavirin (IFN/RBV) combination therapy. To date, anti-RR antibodies have not
been found in treatment-naïve HCV patients or in patients from any other disease groups,
with few reported exceptions. Here, we describe recent advances in characterizing the
RR structure and the strong association between anti-RR antibody response and HCV
patients treated with IFN/RBV, detailing why anti-RR can be considered a human model of
drug-induced autoantibody generation.
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INTRODUCTION
Autoantibodies targeting rods and rings (RR) have become an
intriguing topic of discussion since 2005, when the unique RR
pattern was first observed in a standard IIF-HEp-2 assay. Patient
sera presenting this novel staining pattern were recognized to be
hepatitis C virus (HCV) patients treated with the typical pegylated
interferon-α/ribavirin combination therapy (IFN/RBV). Histori-
cally, HCV infection has been loosely associated with a collec-
tion of different types of autoantibodies, including antinuclear,
anti-smooth muscle, and anti-liver/kidney microsome antibodies,
among many others. The production of anti-rods/rings (anti-RR)
antibodies appears to be distinct from current knowledge of typi-
cal autoantibody generation in HCV patients. There are presently
a few hypotheses attempting to explain how antibodies targeting
self-proteins are generated, including suggestions that apoptotic
bodies, epigenetic modifications, or cross-reactivity between self-
proteins and foreign proteins, known as molecular mimicry, may
play a role in autoantibody generation (1). Anti-RR antibodies
seem to have an additional stipulation that has been reported
by several independent laboratories: treatment with IFN/RBV is,
with few exceptions out of all patients reported to date, required
to observe anti-RR seropositivity; anti-RR antibodies have not
been observed in any HCV patients prior to treatment (2–6).
This implies that anti-RR antibodies should be considered drug-
induced autoantibodies, similar to previously documented cases
Abbreviations: ANA, antinuclear antibody; CTPS1, cytidine triphosphate syn-
thetase 1; DON, 6-diazo-5-oxo-l-norleucine; HCV, hepatitis C virus; IFN/RBV,
pegylated interferon-α/ribavirin therapy; IMPDH2, inosine monophosphate dehy-
drogenase 2; RIPA, radioimmunoprecipitation assay; RR, rods and rings.
of antinuclear and anti-histone antibodies in drug-induced lupus
erythematosus, which has been demonstrated in both humans and
mice (7). The story of anti-RR antibodies becomes more com-
pelling when one considers that when the RR ANA pattern was
first observed, the antigenic filamentous and annular structures
targeted by these antibodies were completely unfamiliar to the
field. In recent years, our laboratory and other laboratories, who
stumbled upon the same structure in mammalian cells through
different means, have begun to elucidate the structural and func-
tional characteristics of these previously unknown autoantigens
(8–11). In the following sections, we present anti-RR antibodies
as a human model for drug-induced autoantibody generation, as
well as report recent findings on the unusual enzymatic polymers
known as RR that are targeted by these antibodies.
AUTOANTIGENIC ROD AND RING STRUCTURES
In order to properly discuss anti-RR as a human model of autoan-
tibody generation, it is necessary to first present current knowledge
of the novel targets of these antibodies, since the process of elu-
cidation of the RR structures has only been ongoing for less than
a decade. Morphologically, RR structures present themselves in
two major forms, discrete filamentous “rods” 3–10µm in length
or annular “rings” 2–5µm in diameter (Figure 1). Both forms are
observed primarily in the cytoplasm, although generally smaller
structures are regularly found in the nucleus under cellular condi-
tions allowing for RR formation (5). While it has been shown that
RR are not associated with any known organelles, we have observed
perinuclear rods that appear to wrap around or position along the
cytoplasmic side of the nuclear membrane (2, 8). The primary
target and major component of the RR structures is the enzyme
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FIGURE 1 | Rods and rings induced under various conditions exhibit
similar phenotypic patterns. (A) Autoantibodies in prototype anti-RR serum
604 from a hepatitis C patient (green, DyLight 488 donkey anti-human IgG)
recognize RR structures in a standard HEp-2 ANA screening; nuclei are
counterstained with DAPI (blue). Serum 604 also shows fine nuclear speckled
staining. (B) RR induced by 24 h treatment with 1 mM ribavirin in HeLa cells
are detected by another human prototype hepatitis C serum It2006 (green,
Alexa Fluor 488 goat anti-human IgG); nuclei counterstained with DAPI (blue).
(C) HeLa cells deprived of glutamine for 48 h exhibit RR in ~50% of cells and
are recognized by serum It2006 (green, Alexa Fluor 488 goat anti-human IgG);
nuclei counterstained with DAPI (blue). Under each condition, nuclear rods
(arrowheads) can be clearly visualized alongside more conspicuous
cytoplasmic rods and rings, which typically appear much longer and thicker
than their nuclear counterparts; rings can also be found in the nucleus,
although this is a less common observation. Additionally, while cytoplasmic
RR appear to be more common than nuclear RR, rods often localize to the
perinuclear region (arrows). All panels are shown at 200×magnification. Scale
bar: 10µm.
Table 1 | Associations between RR-inducing inhibitors and anti-RR production.
Inhibitor Mode of action Clinical use Anti-RR in patients? Major references
Acivicin Glutamine analog N/A (experimental antitumor agent) None reported (8)
Decoyinine Nucleoside analog N/A (experimental antitumor agent) None reported (11)
DON Glutamine analog N/A (experimental antitumor agent) None reported (8)
Mycophenolic acid Inhibits IMPDH Prevention of organ transplant rejection; lupus nephritis None reported (10)
Pemetrexed Folate antimetabolite Pleural mesothelioma; non-small cell lung cancer None reported (5)
Ribavirin Inhibits IMPDH Hepatitis C; human respiratory syncytial virus Yes, 20–38% of HCV patientsa (2, 3)
DON, 6-diazo-5-oxo-l-norleucine; IMPDH, inosine monophosphate dehydrogenase;
aanti-RR observed in 20–38% of hepatitis C patients treated with pegylated interferon-α/ribavirin combination therapy.
inosine monophosphate dehydrogenase type 2 (IMPDH2), which
functions primarily in the GTP biosynthesis pathway by catalyzing
the rate-limiting conversion of inosine monophosphate into xan-
thosine monophosphate. IMPDH2 and its other isoform IMPDH1
share 84% sequence identity, but while several laboratories have
identified IMPDH2 as the main contributor to formation of RR,
none have yet been able to definitively determine the contribu-
tion of IMPDH1 (2, 4, 8–11). Since anti-RR antibodies were first
observed in the sera of HCV patients treated with IFN/RBV, both
interferon-α and ribavirin were tested in vitro to determine their
effects on cultured cells; while IFN had no effect on RR forma-
tion, the IMPDH inhibitor ribavirin induced RR formation in
>95% of cultured cells (2, 8, 11). Previous reports showed that
another IMPDH inhibitor, mycophenolic acid, induced RR in a
high percentage of cultured cells (Table 1) (10, 11).
A previous study from our laboratory also identified cytidine
triphosphate synthetase type 1 (CTPS1) as an additional com-
ponent of RR (8). CTPS, which also has two isoforms with 74%
sequence identity, is responsible for the rate-limiting conversion
of uridine triphosphate to cytidine triphosphate. Two glutamine
analogs, 6-diazo-5-oxo-l-norleucine (DON) and acivicin, which
non-specifically inhibit CTPS by nature of their similarity to
glutamine, have also been reported to induce RR formation in vitro
(8). Curiously, despite the existence of several drugs that can
induce RR formation in vitro, IFN/RBV-treated HCV patients are
the only patients we have seen develop antibodies targeting these
structures to date (Table 1). There has been some debate over the
past couple of years regarding the contribution of CTPS to RR for-
mation. Since our 2011 study that identified CTPS as a potential
component of RR using an antibody targeting Drosophila CTPS,
we have been unable to validate the presence of CTPS in RR with
any commercially available CTPS antibodies (5). Additionally, we
have yet to observe any patient sera that react with CTPS, despite
demonstrating that a number of anti-RR sera react positively with
IMPDH (6, 12). Certainly, we are still in the early stages of fully
expounding the structural details of RR, and we may yet find a
more definitive link between CTPS and IMPDH by way of this
unique structure.
Although the study of RR in vitro was initiated using small-
molecule inhibitors to induce structure formation, RR have been
observed in other circumstances in the absence of these inhibitors.
Certain non-human cell lines have been found to continuously
express RR without treatment with inhibitors, such as normal rat
kidney epithelial cells (NRK), male rat kangaroo kidney epithelial
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cells (Ptk2), primary mouse fibroblasts (3T3), mouse leukemic
monocyte/macrophage cells (RAW264.7), and Chinese hamster
ovary cells (CHO) (5, 6). These various cell lines present RR in
anywhere from 10 to 80% of cells, depending on the cell type. The
most notable and impressive example is the steady occurrence
of RR in undifferentiated mouse embryonic stem cells; the typi-
cal observed ratio of 9:1 rods to rings is reversed in this cell type,
which show a 9:1 rings to rods ratio (8). While it is not uncommon
for mouse cell lines to present RR without apparent manipulation
or induction of the structures, this unusual ratio implies that the
structures in these cells have the potential to be structurally or
functionally different. Recent work from our laboratory points to
another method of inducing these structures through glutamine
deprivation (9). In that study, HeLa cells deprived of glutamine for
at least 48 h developed RR in ~50% of cells; the percentage of cells
presenting RR increased to ~98% (similar to IMPDH inhibitors)
when depletion of exogenous glutamine was combined with treat-
ment of methionine sulfoximine, a glutamine synthetase inhibitor.
These reported phenotypic differences in RR expression between
cells treated with inhibitors, cells presenting RR without extrin-
sic manipulation, and cells deprived of glutamine suggest that
functionality of the structures may vary depending on cellular
conditions, although at this time we can only speculate on func-
tional differences because no direct evidence has been reported
yet. At least, the presence of IMPDH2 and reactivity with proto-
type anti-RR sera has been validated in all forms of RR observed
in mammalian cells to date, so it can be concluded that we are
observing the same structures under all of these conditions.
EXCLUSIVITY OF ANTI-RR IN IFN/RBV-TREATED HCV
PATIENTS
While only a few studies have been completed to date examin-
ing the prevalence of anti-RR positivity in HCV and other disease
cohorts, a handful of common trends in the data have already
emerged. In 2011, one of the first reports on anti-RR came out that
used radioimmunoprecipitation (RIPA) to analyze the prevalence
of anti-IMPDH2 antibodies in various disease groups; using this
technique, they reported the presence of anti-IMPDH2 in 35.2% of
HCV-RNA carriers (n= 108), compared to 31% of anti-actin pos-
itive patients suspected of autoimmune hepatitis (n= 42), 5% of
hospitalized HCV-RNA negative patients (n= 100), 6.2% of HBV-
DNA positive patients (n= 113), 13.7% of antinuclear antibody
positive patients (n= 51), 3.2% of anti-mitochondrial positive
(type M2) patients suspected of primary biliary cirrhosis (n= 31),
and 2% of healthy blood donors (n= 100) (13). Although anti-RR
is not exactly the same as anti-IMPDH2, we can speculate that this
increased prevalence of anti-IMPDH2 in HCV-RNA carriers could
be related to IFN/RBV therapy potentially altering the immuno-
genicity of IMPDH2 protein. In early 2012, another study reported
clinical relevance of anti-RR in a cohort of 75 IFN/RBV-treated
HCV patients from Italy (2). Although some preliminary work
was presented on some small cohorts of patients prior to this pub-
lication, this study resulted in the first indications of general trends
seen with the anti-RR pattern to date. Despite the fact that exten-
sive work on HCV has been published over the last few decades, it
was not until recently that the anti-RR pattern was observed. This
may have been largely due to the fact that only a few commercial
HEp-2 substrate slides have been shown to detect anti-RR to date,
those from INOVA Diagnostics (San Diego, CA, USA) or Euroim-
mun (Lübeck, Germany), for example. For reasons still unknown,
the cells in these slides contain the RR structures necessary to detect
anti-RR, while the cells in slides from many other companies do
not. In this study by Covini et al., substrate from INOVA Diagnos-
tics led to the observation that 15 out of 75 HCV patients (20%)
who received IFN/RBV treatment were positive for these anti-RR
antibodies reacting with these unique filamentous RR structures
(2). This observation was especially noteworthy since anti-RR were
not detected in the sera of the same patients that were collected
prior to antiviral therapy, and these antibodies were not detected
in sera of patients from any other control groups, which included
105 primary biliary cirrhosis, 43 primary sclerosing cholangitis, 56
autoimmune hepatitis, 100 untreated hepatitis B-related chronic
active hepatitis, and 100 hepatocellular carcinoma patients, as well
as 100 blood donors. Additionally, the authors noted that patients
who did not respond to therapy or relapsed were significantly
more likely to be anti-RR positive (10/30, 33%) than patients who
responded well to IFN/RBV therapy (5/45, 11%). Although this
study has been succeeded by additional work on other patient
cohorts, some salient hypotheses made in the discussion have yet
to be answered.
While there are some well-known cases in the field of hepa-
tology of drugs inducing autoantigens, those reported thus far
are organ-specific responses. RR are the first reported case of
induction of an autoantigen related to IFN/RBV treatment in
HCV patients. In the same study from Covini et al., they showed
that in vitro treatment of cell lines with RBV induced the for-
mation of RR structures, leading them to hypothesize that RBV
could be inducing structure formation in vivo as well, perhaps in
hepatocytes during the process of antiviral therapy, which would
eventually lead to an immune response in the form of anti-RR.
An additional consideration is that the exclusivity of the associa-
tion of anti-RR with treated HCV patients suggests a potential for
a biological role for the RR structures, since in this initial study,
anti-RR were significantly more prevalent in non-responders and
relapsers than in patients responding to IFN/RBV therapy. While
it is still not known why RR structures appear to become antigenic
in HCV-IFN/RBV patients but not in patients treated with other
drugs known to induce these structures in vitro, it is at least striking
that RBV, an inhibitor of IMPDH, may be causing rearrangement
of the same enzyme into a structure presented to the immune
system as antigenic.
Although the study from Covini et al. reported that patients in
their cohort who did not respond to therapy or relapsed were
significantly more likely to be anti-RR positive, results from a
follow-up study comparing the anti-RR titers and serum reactivity
with anti-IMDPH2 between two new patient cohorts led to some
unexpected results (4). In one cohort of 46 Italian HCV patients
positive for anti-RR, significantly higher titers were found in
patients who relapsed from therapy compared to non-responding
(p= 0.004) or responding (p= 0.015) patients. Patients from a US
cohort (n= 47) who did not respond or relapsed had significantly
higher titers than responding patients (p= 0.0016). Analysis of
the two cohorts using RIPA showed that anti-RR antibodies were
primarily anti-IMPDH2 in 96% of patients in the Italian cohort,
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compared to only 53% in the US cohort; this is a strong indi-
cation that the RR structures are composed of other unknown
proteins that may become antigenic in certain patients. It should
be noted that no laboratories have determined any anti-RR pos-
itive patient sera to be reactive with CTPS to date (4, 6, 12). A
longitudinal study published just after this report confirmed the
previous trend observed in the Covini et al. paper, reporting that
38% of 108 treated HCV patients were positive for anti-RR while
none of the 166 untreated HCV patients or patients receiving only
interferon-α (n= 23) or only ribavirin (n= 3) presented posi-
tive anti-RR staining (3). Notably, they also reported that anti-RR
positivity appeared after 3–6 months of treatment and remained
in a percentage of Brazilian IFN/RBV-treated HCV patients 6–
12 months post-treatment. Another publication with the Brazilian
HCV cohort addressing the behavior of anti-RR antibody produc-
tion during IFN/RBV treatment shows that the temporal kinetics
of the humoral autoimmune response to IMPDH2 resembled that
of a conventional humoral response to infectious agents regarding
titer, avidity maturation, and isotype levels, but showed a consid-
erably slower pace in titer increase and avidity maturation, as well
as in isotype class switch (14). Yet another study from 2013 once
again validated the apparent exclusivity of anti-RR to IFN/RBV-
treated HCV patients; in this study, anti-RR antibodies were not
observed in any primary biliary cirrhosis or systemic lupus ery-
thematosus sera, and prior treatment with IFN/RBV was the only
independent predictor of anti-RR positivity in a cohort of Cana-
dian patients (6). Although they reported that only 5% of their
patient cohort was positive for anti-RR, they acknowledged that
the large majority of their patients were treatment-naïve, which
explains the lower percentage compared to previous studies. Either
way, there are clearly a few independent data sets from varying
geographic regions of the world that support the hypothesis that
anti-RR antibodies are a model for drug-induced autoantibody
generation.
Despite the evidence supporting the exclusivity of anti-RR
with IFN/RBV treatment, certainly some rare exceptions have
been reported where anti-RR antibodies have been observed in
patients naïve to IFN/RBV. The most notable exception to the
premise of exclusivity lies in the results from the National Health
and Nutrition Examination Survey (NHANES), where 0.8% of
4,754 individuals from the US, designed to be representative of the
general US population, were reported anti-RR positive (15). Inter-
estingly, anti-RR titers in the NHANES patients were measured to
be significantly lower (median= 1:320) than the titers in the US
and Italian HCV cohorts from Carcamo et al. (medians= 1:1600
and 1:25,600, respectively), a potential sign that low-titer anti-
RR may occur rarely in the general population and may not be
associated with a certain disease or treatment, while high-titer
anti-RR may be associated with IFN/RBV (15). To date, there have
also been two individuals with no known association with rib-
avirin reported to be positive for anti-RR, one hepatitis B patient
and one systemic lupus erythematosus patient; the implications of
these two patients’ reactivity with RR have yet to be determined
(3, 15). However, with current evidence, we can conclude that in a
vast majority of cases, anti-RR antibodies are likely to be related to
IFN/RBV treatment and could therefore be considered a unique
model for drug-induced autoantibody generation.
CONCLUSION
Rods and rings and the autoantibodies that target these struc-
tures have become a major interest for several laboratories around
the world. When some of the more surprising data about this
antibody/antigen relationship are considered, it is easy to see the
potential for anti-RR to develop as a truly unique example of
autoantibody generation in humans. For example, it is not often
that titers up to 1:819,200 are reported in literature (4), and it
is not often that subcellular structures as large as RR go unno-
ticed for so long. On top of that, IMPDH is a vital enzyme
for proliferation and viability in the cells of diverse species, and
one can see the potential for these structures to play crucial
roles in homeostasis and metabolism, as has been suggested in
recent studies (8–11). For now, the study of the possible clin-
ical impact of these antibodies and the study of the composi-
tion and function of the RR structures must continue, with the
hope that the clinical and basic science aspects of this system
will eventually be bridged to help improve the lives of patients
and to bolster our knowledge of large, potentially immunogenic
enzymatic aggregates in the cell. Since high-titer anti-rods/rings
autoantibodies appear to be somewhat exclusive to IFN/RBV-
treated HCV patients, it is reasonable to hypothesize that the
combination of IFN/RBV and HCV creates a unique situation
in which HCV gene products have a special affinity for RR struc-
tures. This putative RR/HCV structure could become autoanti-
genic and lead to production of autoantibodies, especially under
the influence of IFN. It is likely that many or all of the drugs
listed in Table 1 could induce RR in vivo, but perhaps an excep-
tional interaction with HCV enables RR to present as autoanti-
genic in a subset of HCV patients that cannot occur in other
diseases.
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